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Interest  in  how  diet  inﬂuences  brain  function  via  the  gut  microbiome  is growing.
Butyrate  can  protect  the  brain  and  enhance  plasticity  in neurological  disease  models.
Gut  microbiota  produce  butyrate  by  fermenting  carbohydrates  in  a  high  ﬁber diet.
Hypothesis:  A  high  ﬁber  diet  can  elevate  butyrate  to prevent/treat  brain  disorders.
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a  b  s  t  r  a  c  t
As  interest  in the  gut microbiome  has  grown  in  recent  years,  attention  has  turned  to the  impact  of  our  diet
on our  brain.  The  beneﬁts  of  a high  ﬁber  diet  in  the  colon  have  been  well  documented  in  epidemiological
studies, but  its potential  impact  on  the  brain  has  largely  been  understudied.  Here,  we  will review  evidence
that  butyrate,  a short-chain  fatty  acid (SCFA)  produced  by  bacterial  fermentation  of  ﬁber  in  the  colon,  can
improve  brain  health.  Butyrate  has  been  extensively  studied  as a histone  deacetylase  (HDAC)  inhibitoreywords:
ut-brain axis
euroepigenetics
utyrate
igh ﬁber diet
ut microbiome
but  also  functions  as  a ligand  for a  subset  of  G protein-coupled  receptors  and  as  an  energy metabolite.
These  diverse  modes  of action  make  it well  suited  for solving  the  wide  array of  imbalances  frequently
encountered  in  neurological  disorders.  In this  review,  we  will integrate  evidence  from  the  disparate  ﬁelds
of gastroenterology  and  neuroscience  to hypothesize  that the  metabolism  of a  high  ﬁber  diet  in the gut
can alter  gene  expression  in the  brain  to prevent  neurodegeneration  and promote  regeneration.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Summary of the proportions of SCFA produced with different forms of carbohy-
drates. Adapted from Smith et al. [102].
Proportion of SCFA energy (kJ) produced
Carbohydrate Butyric acid Propionic acid Acetic acid
Cellulose 0.33 0.24 0.43
Gum arabic 0.17 0.28 0.56
Lactulose 0.36 0.16 0.48
Oat  bran 0.38 0.24 0.38
Pectic substances 0.32 0.17 0.51
Resistant starch 0.55 0.21 0.24
and transcriptional dysfunction are characteristics of many neu-
rodegenerative diseases [19]. Thus, HDAC inhibitors have become
attractive therapeutic candidates due to their ability to increase
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. Introduction
The relationship between our gut microbiota and nervous sys-
em is a large part of the gut-brain axis that has attracted increasing
nterest in recent years. It is estimated that 90% of the cells in
he human body are of microbial origin, and the vast majority of
hese microbiota are comprised of 15,000–36,000 species of com-
ensal and symbiotic bacteria that reside within the lumen of the
ut [1,2]. A diverse microbial community is crucial for our health
nd disease prevention based on microbiome studies (i.e., metage-
omic sequence analyses) and perturbed energy homeostasis that
as been observed in germ free mice [3]. Although it is not yet clear
ow gut microbiota positively and negatively affect brain func-
ion, multiple mechanisms are likely to be involved. Gut bacteria,
ave a prodigious metabolic capacity and some microbe-derived
etabolites enter the circulation and can cross the blood-brain
arrier. There is growing evidence that these microbes produce
eurotransmitters, such as GABA and serotonin, modulate the
mmune system, alter epigenetic markers and produce bioactive
ood components and energy metabolites [2,4,5]. Thus, dietary
anipulation to achieve a symbiosis that can improve the health of
he microbiome and our brains is an attractive idea currently under
nvestigation.
In this review, we will focus on the short chain fatty acid (SCFA),
utyrate, which is most commonly produced by bacteria in the
olon, and its role as a potential therapeutic for neurological dis-
ases. Butyrate is an attractive therapeutic molecule because of its
ide array of biological functions, such as its ability to serve as
 histone deacetylase (HDAC) inhibitor, an energy metabolite to
roduce ATP and a G protein-coupled receptor (GPCR) activator.
harmacologically, butyrate has had a profoundly beneﬁcial effect
n brain disorders ranging from neurodegenerative diseases to psy-
hological disorders. In this review, we will discuss how butyrate
s made and the pharmacological effects of butyrate in neurologi-
al disorders. Finally, we will summarize the current evidence that
igh ﬁber, butyrate-producing diets are capable of improving the
ealth of our brains.
.1. Sources of butyrate
Butyrate is synthesized via the fermentation of otherwise non-
igestible ﬁber by bacteria in the colon. Two acetyl CoA molecules
re condensed into acetoacetyl CoA, which is converted through
(+)-beta-hydroxybutyryl CoA and crotonyl CoA intermediates to
utyryl CoA. Butyryl CoA is then converted to butyrate either by
utyrate kinase or butyryl CoA and acetate CoA transferase (as
hown in Fig. 1) [6,7].
Bacteria, such as those from the Clostridium, Eubacterium, and
utyrivibrio genera, are able produce butyrate in the gut lumen at
M levels [7,8]. In addition to producing butyrate as an endpoint,
acteria produce fermentation intermediates, including lactate,
uccinate or formate, which are used by the bacteria themselves
o proliferate and survive [9,10]. Butyrate is also utilized by micro-
iota and serves as the primary energy source of colonocytes (as
iscussed below), making this a vital and mutually beneﬁcial rela-
ionship. High ﬁber foods, summarized in Table 1, that enable these
utyrate-producing bacteria to thrive include resistant starches
e.g., whole grain and legumes) and fructo-oligosaccharides (FOS)
e.g., bananas, onions, and asparagus). In fact, within two weeks of
 high FOS diet, rats showed increase butyrate in the large intestine
ithout changing the total number of anaerobic bacteria [11]. Sim-lar results were seen in another study with diets containing FOS as
ell as resistant starches, but were not observed in the starch free
heat bran diet, which produces less butyrate [12]. This study, as
ell as many others, demonstrates that different sources of ﬁberWheatbran 0.34 0.23 0.42
Xylan 0.06 0.23 0.71
yield different levels of butyrate so care must be used in selecting
the appropriate ﬁber diets to increase butyrate levels.
Aside from being produced by bacterial fermentation, butyrate
can also be produced in much lower concentrations by mammalian
cells through fatty acid oxidation and glucose metabolism [13,14]
and can be found in plant oils and animal fats [4]. Butyric acid (the
acid form of butyrate) is also present in the milk of ruminant ani-
mals, such as cows. Butter contains 3–4% butyric acid, in the form
of tributyrin (butyryl triglyceride), making it the richest dietary
source of butyrate [15]. Interestingly, the term butyrate originates
from the Greek word for butter [16,17]. One molecule of tributyrin
is metabolized into three butyrate molecules by intestinal enzymes.
Tributyrin (1 g/kg) was  able to elevate portal vein concentrations
of butyrate to 2.4 mM after 1 h in rats [18].
1.2. The functions of butyrate
1.2.1. Histone deacetylase inhibitor
Histone acetylation is a post-translational modiﬁcation by an
epigenetic protein, which are proteins that bind to chromatin and
inﬂuence chromatin structure to change the propensity that a gene
is transcribed or repressed. Acetylated histones cause the chro-
matin structure to loosen by weakening electrostatic attraction
between the histone proteins and the DNA backbone. This pro-
cess enables transcription factors and the basal transcriptional
machinery to bind and increases transcription. Acetyl groups are
added to highly conserved N-terminal l-lysine residues by histone
acetyltransferases (HATs) and removed by histone deacetylases
(HDACs). Reduced HAT activity, lower global histone acetylationFig. 1. Schematic representation of the carbohydrate fermentation pathways that
lead  to butyrate production in the large intestine. The ﬁnal enzymes involved in
the  formation of butyrate are: (a) Butyryl CoA:acetate CoA transferase (b) Phospho-
transbutyrylase/butyrate kinase. Adapted from Pryde et al. [7].
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istone acetylation and promote the expression of prosurvival,
roregenerative and proplasticity genes.
Sodium butyrate (NaB), the sodium salt form of butyrate com-
only used in pharmacological studies, is a well-known HDAC
nhibitor that results in increased histone acetylation when applied
o cells in culture in the high micromolar range [20,21]. Studies from
ur own lab demonstrated that NaB treatment could resist oxida-
ive stress in vitro and in vivo [22–25]. These salutary effects were
ighly correlated with HDAC inhibition as a mechanism of protec-
ion. In multiple models of Huntington’s disease, we  have shown
hat NaB and phenylbutyrate, a structurally similar analog, rescues
istone acetylation, prevents neuronal cell death and extends the
ifespan of mice [23,26].
Numerous subsequent studies have shown that NaB’s salutary
ffects span many neurological disease models and aspects of the
athophysiology of disease. For example, NaB can protect neurons
rom cell death in models of Parkinson’s disease [27–29] and in
isplatin-induced hearing loss [30], where NaB was able to reverse
he disease-associated reduction in histone acetylation. Similarly,
aB was able to reduce the infarct size in models of ischemic stroke,
imiting the damage to the brain and improving behavioral out-
omes [24,31–33]. In vitro and in vivo (via intraperitoneal injection)
ata from our own laboratory also suggests that butyrate can induce
esistance to oxidative stress and increase histone acetylation and
nhance gene expression of a number of genes in the high micro-
olar range [24,34]. Altogether, these observations are consistent
ith the idea that NaB can modulate the expression of a large num-
er of genes to affect numerous pathophysiological pathways. The
rospect of accomplishing this goal with a single, naturally occur-
ing small molecule is exciting.
NaB has also demonstrated a profound effect on improving
earning and memory, particularly in cases of disease-associated
r toxicity-induced dementia. In mouse models of Alzheimer’s
isease, histone acetylation is restored and expression of learning-
ssociated genes is increased with NaB treatment [35,36]. While
aB had no effect on the contextual memory on wild-type mice,
ontextual memory in the transgenic mouse model showed sig-
iﬁcant improvements, even at late stages of Alzheimer’s disease.
hese improvements in learning and memory have also been
emonstrated in models of memory impairment from a toxic over-
oad of metals [37,38], traumatic brain injury [39] or neurological
nfections [40,41].
As HDAC inhibitors inﬂuence the transcription of numerous
enes, it seems unlikely that a single gene is responsible for its neu-
otrophic effects. However, many studies have shown that at least
ome of these beneﬁcial effects can be attributed NaB’s ability to
ncrease acetylation around the promoters of neurotrophic factors,
uch as BDNF, GDNF and NGF and thus increasing their transcrip-
ion [41–48]. Other studies have demonstrated the importance of
mmediate early genes, including c-Fos and Homer1a, which are
ctivity dependent genes involved in plasticity [44,49–52]. Based
n these data, NaB is capable of upregulating a suite of genes that
romote survival, plasticity and regeneration.
It should also be noted that the effects of HDAC inhibitors are
ot speciﬁc to histone proteins alone. In fact, a growing list of over
700 proteins can be acetylated on their lysine residues, and HDAC
nhibitors block their deacetylation as well [53]. Thus, the effect of
DAC inhibitors on non-histone proteins should not be overlooked.
cetylation plays an important role that affects the enzymatic and
etabolic activity of many proteins. For example, our group has
hown the transcription factor Sp1 is acetylated and activated by
xidative stress, and butyrate, as well as other HDAC inhibitors, can
nhance this protective adaptive response to promote cell survival
22,23,54].e Letters 625 (2016) 56–63
1.2.2. Metabolism and mitochondria
Butyrate plays two  major roles in metabolism and mitochon-
drial activity. First, butyrate can serve as an energy substrate. In fact,
colonocytes have adapted to use butyrate as their primary source
of energy, which accounts for approximately 70% of ATP produced
[55]. Given overwhelming use of butyrate as an energy substrate
in the colon and the microbiome, much of the research to date has
focused on its metabolic effects in the colonic epithelium. It was
recently shown that germ free mice, which lack a microbiome, had
a signiﬁcantly reduced NADH/NAD+ ratio and reduced ATP levels
in the colon compared to conventionally raised mice with a normal
microbiome [56]. Butyrate was  able to rescue the diminished mito-
chondrial respiration in the germ free mice, which demonstrates its
importance in energy homeostasis. It was  also found that cancer-
ous colonocytes undergoing the Warburg effect, deﬁned by their
preferential use of glycolysis rather than mitochondrial respiration,
allows butyrate to accumulate in the nucleus where it can act as
an HDAC inhibitor [57]. However, in normal coloncytes the cells
rapidly utilize butyrate for energy via mitochondrial -oxidation.
Interestingly, mitochondrial metabolism of butyrate does produce
more acetyl-CoA, which can be used by HATs to add acetyl groups to
proteins so under either condition butyrate could in theory increase
acetylation and affect gene transcription.
While the metabolic events in the colon may appear discon-
nected from that of the brain, it’s important to consider the
immense energy demands of the brain and the energy dyshome-
ostasis that occurs in the brain in many neurological diseases.
Perhaps the best cited example is the reduced glucose utilization in
the Alzheimer’s brain, which occurs at the earliest stages of the dis-
ease and well before memory loss [58,59]. This reduction in glucose
utilization has prompted a number of studies to identify thera-
peutic strategies to provide alternative sources of energy to fulﬁll
the brain’s energy requirements. For example, the use of caprylic
triglycerides as a medical food to enhance ketogenesis via increas-
ing -hydroxybutyrate has been shown to improve cognitive scores
in Apo-E4 negative Alzheimer’s disease patients after 45 days [60].
Longer time points were less successful, but it is likely that these
treatments would need to begin before signiﬁcant cognitive symp-
toms to achieve maximum effectiveness. Currently no studies have
examined the metabolic effect of gut-derived butyrate on the brain.
However, we  hypothesize that if sufﬁcient butyrate levels could be
reached in the brain, butyrate could stand in as an energy substrate,
as in the colon, and restore energy homeostasis, but the precise con-
centration to affect brain physiology via changes in the diet, gut
microbiome or through pharmacological supplementation remain
undeﬁned.
Reduced brain glucose availability is believed to contribute to
mitochondrial dysfunction in acute and chronic neurological dis-
eases but could, in theory, be aided by the presence of butyrate’s
direct and indirect effects on energy metabolism. In this context,
butyrate can: (1) directly affect energy metabolism by acting as a
substrate for beta-oxidation; (2) can upregulate genes involved in
mitochondrial biogenesis (e.g., PGC1) via its effects as a selective
HDAC inhibitor; and (3) via its ability to affect the acetylation of
a wide number of metabolic proteins. This last effect of butyrate
and other HDAC inhibitors on metabolism was brought to light by
the studies demonstrating that nearly every enzyme involved in
glycolysis, gluconeogenesis, the TCA cycle, fatty acid metabolism
and glycogen metabolism is acetylated [61]. The potent HDAC
inhibitor, TSA, was able to signiﬁcantly increase acetylation of
these proteins. In the case of malate dehydrogenase, acetylation
was increased by both glucose and TSA to lead to increased activ-
ity levels. To a large degree, these studies have been replicated
with NaB by the lab of João Quevedo, which showed that NaB
can restore Complex I–IV, as well as the TCA cycle activity, after
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eing repressed by amphetamines and ouabain in animal mod-
ls of mania [62–64]. These studies demonstrate that butyrate is
lso capable of increasing mitochondrial activity, which can help
o rectify the disease-associated mitochondrial dysfunction in the
rain.
.2.3. Protein-coupled receptor activator
G protein-coupled receptors (GPCR) are the largest and most
iverse family of transmembrane proteins. They are comprised of
 transmembrane -helices, which bind extracellular signals, such
s light-sensitive compounds, hormones, growth factors and neu-
otransmitters, and activate signal transduction pathways inside
f the cell, primarily the cAMP and phosphatidylinositol signal-
ng pathways [65]. With the role in detecting extracellular signals,
PCRs are critical for a number of physiological functions including
egulation of immune system, autonomic nervous system regula-
ion, sensory (taste and smell) function, and maintaining energy
omeostasis. Dysfunction of GPCRs is associated with a number of
iseases, which has made them the target for more than 40% of
rescribed drugs [4].
In 2003, two previously orphan GPCRs, with no known lig-
nds (GPR41 and GPR43), were identiﬁed as receptor targets for
CFA and aptly renamed free fatty acid receptors (FFAR) 3 and 2,
espectively. Although GPR41 and GPR43 are related showing 52%
equence similarity and identiﬁed as tandemly encoded genes in
hromosome 19, they differ on their preference in chain length of
he SCFA ligands. FFAR2 is more speciﬁc to the shorter aliphatic
hains of acetate and propionate, while FFAR3 preferentially binds
ropionate, butyrate and valerate [66].
FFAR3 appears to play a signiﬁcant role in balancing energy
etabolism through intestinal gluconeogenesis (IGN) and the sym-
athetic nervous system [67]. FFAR3 is highly expressed in the
ympathetic nervous system and knockout of FFAR3 in mice show
educed sympathetic ganglion activity. What is most intriguing is
hat while it has been demonstrated that SCFA (propionate) activate
he ganglia activity via FFAR3, the ketone body, -hydroxybutyrate,
hich is produced under conditions of starvation or ketosis but
tructurally similar to butyrate, inhibits ganglia activity by func-
ioning as an antagonist to FFAR3. Although both butyrate and
ropionate are agonists of FFAR3 in the nervous system, only pro-
ionate uptake in the IGN is dependent on FFAR3. This ﬁnding
emonstrates a novel interaction between metabolic substrates
nd sympathetic nervous system activity [68].
Butyrate also signals through GPR109a, which is widely
xpressed in the in colonocytes and T cells, but has also been found
n microglia [69–72]. The expression of GPR109a is reduced in
uman colon cancer cells, and the forced expression of GPR109a
n these cancer cells induces apoptosis [69]. While it requires mil-
imolar concentrations of butyrate to activate these receptors, the
oncentration of butyrate in the colon is more than sufﬁcient to
nhance activity the GPR109a. This has the potentially protect
he healthy colon tissue through its anti-inﬂammatory signaling.
ndeed, butyrate was shown to suppress colonic inﬂammation by
nducing apoptosis in T cells residing in the colon [70]. Interestingly,
nocking down GPR109a (or its transporter Slc5a8) in these cells
ncreased the inﬂammatory response. More recently, it was  shown
hat GPR109a is upregulated in the substantia nigra in Parkinson’s
isease patients, where immunostaining for GPR109a was  colo-
alized with microglia [71]. Treatment with -hydroxybutyrate
nduced anti-inﬂammatory effects in both in vitro and in vivo
odels of Parkinson’s disease through GPR109a activation and
own regulating NF-B activation [72]. The neurons were also
rotected from LPS-induced injury and improved behavioral out-
omes in the animal models. In contrast to the study above, where
-hydroxybutyrate was shown to be an FFAR3 antagonist, here
-hydroxybutyrate is acting as a GPR109a agonist. However, thee Letters 625 (2016) 56–63 59
effect of -hydroxybutyrate with respect to GPCRs appears to
be under signiﬁcant debate, as other groups have identiﬁed -
hydroxybutyrate as a FFAR3 agonist [73]. However, the Parkinson’s
disease studies demonstrate that the activation of GPR109a leads to
anti-inﬂammatory effects in the brain and suggest that it is a good
target for therapeutics in PD.
1.3. High ﬁber diets and the brain
High ﬁber diets have numerous reported health beneﬁts in
reducing risk of type 2 diabetes, colon cancer, obesity, stroke and
cardiovascular disease, making it a widely recommended healthy
diet. Many of the reported effects have been associated with the
microbiome and its ability to produce SCFA, like butyrate. Much of
the butyrate produced in the colon is used as an energy source
by the colonocytes, but some butyrate can also exit the colon
through the portal vein, where the liver absorbs another large por-
tion [74,75]. However, the distal colon is not connected to the portal
vein, allowing for some systemic butyrate to be circulated. Indeed,
there are many reports of high ﬁber diets increasing blood levels of
circulating butyrate [75–77]. These later reports raise the possibil-
ity that increases in circulating butyrate could affect CNS function
directly.
To date, only a handful of studies have probed the mechanis-
tic basis surrounding the beneﬁcial neurological effects of the high
ﬁber diet and butyrate. A recent study demonstrated that germ free
mice have increased blood brain barrier (BBB) permeability, when
compared with speciﬁc pathogen free mice containing a healthy
microbiota [78]. The increased permeability was associated with
decreased levels of tight junction proteins, claudin 5 and occludin
in the frontal cortex, hippocampus and striatum. Colonizing the
germ free mice with the butyrate-producing bacteria, Clostridium
tyrobutyricum, or an oral gavage (for 3 days) of NaB restored BBB
permeability to the healthy levels of the pathogen free mice, while
simultaneously increasing brain histone acetylation and expression
of occludin and claudin 5. This study demonstrated the strong and
important connection between the microbiota, butyrate and the
brain. Another study found signiﬁcant immune beneﬁts in the brain
of mice fed a diet high in fermentable (soluble) ﬁber and found
that they recovered faster from endotoxin-induced sickness [79].
Not only did the diet successfully increase all SCFAs in the colon,
but they also found signiﬁcant beneﬁts by attenuating neuroin-
ﬂammation resulting from the diet. Mice fed the soluble ﬁber diet
showed an increase in IL-1RA, a cytokine and inhibitor of the pro-
inﬂammatory, IL-1, in the brain after exposure to the endotoxin,
lipopolysaccharide (LPS) and a decrease in IL-1 and TNF-. IL-4 is a
cytokine shown to increase IL-1RA and as expected IL-4 mRNA was
also increased in the brains of mice on the soluble ﬁber diet after LPS
treatment. IL-4 expression is enhanced by increased histone acety-
lation. Thus, the authors hypothesized that the elevated butyrate
from the dietary ﬁber fermentation may  contribute to the immune
response. In contrast to the soluble ﬁber diets, splenocytes from
mice on the insoluble ﬁber diet did not increase IL-4 production
when exposed to butyrate in vitro.
1.4. The microbiome and cognition
Several studies have examined the beneﬁcial effects of a high
ﬁber diet on memory and cognition. In these studies the diet and/or
microbiome are manipulated to enhance brain function. For exam-
ple, children on a high ﬁber diet demonstrate better cognitive
control (e.g., multitasking, working memory and maintaining focus)
than children who typically ate a lower ﬁber diet [80]. Other stud-
ies have examined the effects of probiotics that would increase
butyrate-producing bacteria. These studies showed that the pro-
biotics reduced anxiety in rats and lowered psychological stress
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n human subjects [81]. A similar study in subjects with chronic
atigue syndrome showed reduced anxiety, a common symptom of
he disease, with the use of probiotics [82]. Another study provided
ealthy subjects with a fermented milk product and used fMRI to
sses changes in the brain [83]. However, no signiﬁcant difference
as observed in fecal microbiota samples in patients who received
he fermented milk product.
Perhaps one of the most interesting brain-microbiome connec-
ions lies in autism, where an overwhelming 70% of autistic children
uffer from gastrointestinal (GI) symptoms [84]. The degree of GI
ymptoms, most commonly diarrhea and bloating, is often posi-
ively correlated with the severity of autism. This correlation has
aunched numerous studies to determine whether the microbiome
f autistic patients differ from those without autism. Indeed these
tudies have found evidence of decreased Biﬁdobacteria and Pre-
otella and higher levels of Lactobacillus, Sutterella and Firmicutes
ased on cultures from fecal samples, and these differences appear
o be independent of diet [84–87]. Some studies have even reported
n alleviation of autism symptoms in children with late-onset
utism with the use of vancomycin, a poorly absorbed antibiotic;
hough the effects quickly diminished after treatment ended [88].
ince many of the bacteria altered in autistic patients are impor-
ant in the fermentation process that produces SCFAs, like butyrate,
dditional studies measured the SCFA content in autistic children.
owever, there are conﬂicting data as to whether or not this change
n microbiota result in an increase or decrease in SCFAs in fecal
amples [84,89]. Regardless, more studies would be necessary to
etermine if a change in SCFAs in the fecal matter is the result of
oor absorption based on the increased gut permeability seen in
utistic patients or excessive fermentation.
Interestingly, it has been hypothesized that elevated SCFAs
n the circulatory system due to increased gut permeability or
bnormal microbiota, may  actually be detrimental to children
ith autism. Recent studies have shown that intracerebroven-
ricular and peripheral injections of propionic acid (one carbon
horter than butyrate) during development results in autistic like
ehavior, including repetitive dystonic behaviors and object pref-
rence [90–94]. These behavioral changes were also observed to
 lesser extent with butyric acid and acetic acid. However, this
henomenon has led to a rodent model of autism using propioniche diseases which may beneﬁt from butyrate treatment or a high ﬁber diet.
acid to induce autistic symptoms [95,96]. In agreement with these
studies is the increased risk of autism with prenatal exposure to
valproate, an anti-seizure and mood-stabilizing drug that is a car-
boxylic acid HDAC inhibitor, like butyrate [97–100]. Given the large
increase in autism diagnoses in recent years, there is a signiﬁcant
interest in understanding the etiology of the disease. While there
are certainly many factors at play, propionic acid has come under
some scrutiny. It has become an increasingly common food preser-
vative due to its antimicrobial properties, which has increased our
exposure to propionic acid [101]. In general, there is overwhelm-
ing evidence of the beneﬁcial effects of butyrate and other SCFAs,
but based on the autism literature some caution is warranted when
considering prenatal exposure and the developing brain.
2. Conclusion
Butyrate is multi-functional molecule that has signiﬁcant poten-
tial as a therapeutic for the brain, both in its pharmacologic and
dietary form. Fig. 2 summaries the various proposed mechanisms
in which butyrate may  inﬂuence brain health in a number of differ-
ent neurological disorders. Pharmacologically, butyrate is capable
of targeting many pathways with multiple mechanisms of action
that are disease speciﬁc. The dietary sources of butyrate through
a high ﬁber diet or a diet rich in natural sources of butyrate is a
highly appealing approach, as it presents a simple and relatively
low risk method to potentially improve outcomes in patients with
brain disorders. Though much more research is needed to under-
stand the effectiveness of these dietary interventions, they remain
promising interventions that, if validated, may  be used in the future
in conjunction with traditional pharmacological treatments. As the
current literature suggests, we  can no longer overlook the impor-
tance of the gut-brain axis and nutrition in disease pathogenesis
and treatment.
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